Clinical Study
QTc Prolongation in Patients Acutely Admitted to Hospital for Psychosis and Treated with Second Generation Antipsychotics
Table 1
Baseline demographics and clinical characteristics.
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Notes. = number of patients with ECG at baseline and/or ECG at discharge; SD = standard deviation; antipsychotic drug naive = no life-time exposure to antipsychotic drugs before index admission; first admission = index admission was the first admission to a mental hospital; misuse = misuse or dependence according to the Clinical Drug and Alcohol Use Scales (CDUS/CAUS); patients with no illicit drug use could be included in the category alcohol use last 6 months; Schz and related = schizophrenia and related disorders: schizophrenia, schizoaffective disorder, acute polymorphic psychotic disorder with symptoms of schizophrenia, acute schizophrenia-like psychotic disorder, and delusional disorder; acute = acute psychosis other than those categorized under Schz and related; affective = affective psychosis; rest = miscellaneous psychotic disorders. All diagnoses are according to ICD-10; PANSS = the positive and negative syndrome scale; CDSS = the Calgary Depression Scale for Schizophrenia; GAF-F = the Global Assessment of Functioning—Split Version, Functions scale; CGI = the Clinical Global Impression, Severity of Illness scale; RBANS = the repeatable battery for the assessment of neuropsychological status. 1Patients with missing diagnoses are not included in the list. |